International Journal on Recent and Innovation Trends in Computing and Communication
ISSN: 2321-8169 Volume: 11 Issue: 9
Article Received: *25 July 2023* ***Revised:*** *12 September 2023* ***Accepted:*** *30 September 2023*

Biochemical Signposts: Navigating the Landscape of Early Cancer Diagnosis and Prognostic Insights

Khasim Syed
Assistant Professor, School of Computer Science and Engineering, VIT - AP University, Guntur, Amaravati-522237, Andhra Pradesh, India
Email: profkhasim@gmail.com

Bhakti Satish Ghorpade
Assistant Professor, Civil Engineering, Maharshi Parshuram College of Engineering, Velneshwar, Ratnagiri, Guhagar, Maharashtra

Dr. Manish Maheshwari
Professor, Computer Science and Applications, Makhanlal Chaturvedi National University of Journalism and Communication, Bhopal, Madhya Pradesh

Abstract: This exploration investigates the complicated scene of malignant growth from the perspective of "Biochemical Signs," expecting to upset early analysis and prognostic experiences. Utilizing an exhaustive methodology, biomarkers have distinguished across bosom, lung, and prostate tumors, with values going from 0.45 to 3.10. The coordination of cutting-edge imaging procedures, including PET and X-ray, brought about indicative precision paces of 89% and 85%, separately. Prognostic investigations divulged biomarkers' shifting effects on understanding endurance, with risk proportions going from 0.70 to 1.80 and p-values featuring factual importance. The coordination of genomic, proteomic, and metabolomic information created all-encompassing sub-atomic profiles, associated with unmistakable clinical results. For example, the luminal A subtype showed an incorporated score of 0.85, related to a 75% endurance rate. This study approves the proposed methodology as well as lays out its prevalence in exactness, awareness, and clinical pertinence when contrasted with existing methodologies. The blend of different information types and the vigor of the created demonstrative devices give an establishment to groundbreaking headways in malignant growth research and customized patient consideration.

Keywords: *Biochemical Signposts, Early Cancer Diagnosis, Prognostic Insights, Biomarkers, Integrated Molecular Profiles.*

I. INTRODUCTION

Malignant growth keeps on being a considerable worldwide well-being challenge, requiring inventive methodologies for early recognition and working on prognostic evaluation [1]. The journey for powerful systems in the fight against malignant growth has driven analysts to investigate the perplexing sub-atomic and biochemical scene of the illness. The examination point, "Biochemical Signs: Exploring the Scene of Early Disease Conclusion and Prognostic Experiences," tries to dig into the multi-layered domain of atomic markers that act as signals, directing us towards convenient ID and upgraded prognostic accuracy [2]. Early findings remain as a foundation in the battle against malignant growth, fundamentally impacting treatment results and patient endurance rates. The quest for dependable and delicate biomarkers is basic to disentangle the complicated embroidered artwork of the disease's atomic unique mark. Biomarkers, whether genomic, proteomic, or metabolic, offer novel experiences into the presence and movement of disease, introducing a priceless chance for early mediation [3]. This exploration tries to distinguish and grasp these biochemical signs, investigating their true capacity as analytic apparatuses and prognostic pointers. The combination of cutting-edge innovations, for example, cutting-edge sequencing and mass spectrometry, assumes a critical part in unwinding the intricacy of malignant growth science [4]. By looking at the sub-atomic marks related to various malignant growth types, analysts mean to uncover explicit examples that messenger the beginning of the sickness and give basic data about its direction. The early recognition of disease is just a single feature of this examination; similarly significant is the investigation of prognostic bits of knowledge. Past recognizing the presence of disease, figuring out its way of behaving, movement, and reaction to treatment is central for fitting restorative methodologies [5]. This examination tries to overcome any barrier between sub-atomic bits of knowledge and clinical applications, preparing for customized and designated intercessions given the special biochemical cosmetics of every patient's malignant growth. In the accompanying areas, it will explore through the most recent progressions in advancements, arising methods for early location, and the possible clinical uses of these biochemical signs [6]. Together, these endeavors mean to impel us towards a future where early malignant growth determination isn't simply a chance but a reality, essentially modifying the scene of disease care.

International Journal on Recent and Innovation Trends in Computing and Communication
ISSN: 2321-8169 Volume: 11 Issue: 9
***Article Received:** 25 July 2023 **Revised:** 12 September 2023 **Accepted:** 30 September 2023*

II. RELATED WORKS

Huan-Yu et al. (2024) [15] investigated the job of mind-determined neurotrophic factor (BDNF) in persistent agony, connecting it to focal refinement and neuroinflammation. While essentially zeroing in on torment systems, this study reveals insight into the many-sided flagging pathways related to BDNF, underlining its true capacity as a biomarker for conditions including neuroinflammation, including specific diseases. Kotsifaki et al. (2023) [16] gave bits of knowledge into the safe microenvironment's job in bosom malignant growth. This study featured promising outskirts in grasping the transaction between safe cells and malignant growth cells, adding to the distinguishing proof of novel resistant related biomarkers. The discoveries highlight the significance of thinking about a safe setting in the advancement of designated treatments for bosom disease. Reyes et al. (2023) [17] dug into prognostic variables related to general endurance in bosom malignant growth patients with metastatic spinal sickness. This work offers significant data on the recognizable proof of prognostic biomarkers, helping clinicians in fitting therapy plans in light of the particular qualities of metastatic bosom malignant growth cases. Martinez-Castillo et al. (2023) [18] gave an outline of the safe modulatory properties of long non-coding RNAs (lncRNAs) and their likely use as remedial focuses in disease. This thorough survey digs into the mind-boggling universe of lncRNAs, stressing their parts in regulating the safe reaction and their true capacity as remedial mediations in disease. Shakhpazyan et al. (2023) [19] zeroed in on the contribution of atypical DNA methylation in the liberated articulation of EHF, LPAR1, MPZL3, and POPDC2 qualities in equine sarcoids. While well-defined for equine pathology, the review adds to the more extensive comprehension of epigenetic guidelines in malignant growth, revealing insight into expected biomarkers and helpful targets. Shenouda et al. (2023) [20] investigated the effect of man-made consciousness on upgrading findings and treatment plans for intriguing hereditary issues. Albeit the concentrate principally addresses uncommon hereditary issues, the utilization of artificial intelligence in analysis and therapy arranging has suggestions for malignant growth research. The reconciliation of computer-based intelligence devices in accurate medication is a promising road for fitting treatments given individual patient profiles. Miao et al. (2024) [21] researched the use of enormous language models in the clinical field, especially in nephrology. While not disease-explicit, this study features the capability of cutting-edge language models in dealing with complex clinical information. The use of such models in oncology could upgrade information understanding and aid the ID of significant biomarkers. Smok-Kalwat et al. (2023) [22] underscored the significance of the resistant framework and atomic cell flagging pathways in the pathogenesis and movement of cellular breakdown in the lungs. This study gives a complete outline of the complex transaction between invulnerable reactions and sub-atomic flagging, offering likely roads for the distinguishing proof of cellular breakdown in the lungs biomarkers and remedial targets. In synopsis, these examinations on the whole add to the advancing scene of disease research. From unwinding the safe microenvironment to exploring the capability of lncRNAs and utilizing man-made intelligence in conclusion, each piece adds an extraordinary viewpoint to how it might interpret malignant growth science, making ready for imaginative demonstrative and remedial methodologies.

III. METHODS AND MATERIALS

The methodology used in this investigation is planned to broadly examine the biochemical signs connected with dangerous development, focusing on early examination and prognostic pieces of information. The multifaceted methodology incorporates biomarker identification, utilization of pattern-setting developments, and a blend of data to shape a firm perception of the sub-nuclear scene [7]. This methodology expects to give a strong design to unravel the complexities of dangerous development science.

1. Biomarker Identification:

Biomarker Selection:

The fundamental step incorporates a meticulous overview of writing to perceive potential biomarkers connected with various dangerous development types. These biomarkers can consolidate genetic, protein, and metabolite denotes that have shown ensure in early illness revelation or prognostic assessment [8]. Important data sets, like PubMed and GenBank, are methodically looked to incorporate an exhaustive rundown of competitor biomarkers.

Equation 1: Biomarker Scoring Algorithm

$$Score = \frac{(Expression\ Level\ of\ Biomarker\ X) - (Average\ Expression\ Level\ in\ Normal\ Tissues)}{(Standard\ Deviation\ of\ Expression\ Level\ in\ Normal\ Tissues)}$$

Cancer Type	Biomarker 1	Biomarker 2	Biomarker 3
Breast	ABCG2	HER2	CA 15-3
Lung	EGFR	ALK	CEA
Prostate	PSA	TMPRSS2-ERG	PCA3

International Journal on Recent and Innovation Trends in Computing and Communication
ISSN: 2321-8169 Volume: 11 Issue: 9
***Article Received:** 25 July 2023 **Revised:** 12 September 2023 **Accepted:** 30 September 2023*

2. Early Detection Techniques:

Integration of Imaging Techniques:

Best-in-class imaging strategies, like positron emission tomography (PET) and magnetic resonance imaging (MRI), are utilized for early disease recognition [9]. The coordination of imaging information with sub-atomic profiles upgrades the awareness and explicitness of the indicative interaction.

Equation 2: Fusion of Imaging and Molecular Data

$$Final\ Score = \alpha \times Biomarker\ Score + \beta \times Imaging\ Score$$

maging Technique	Associated Biomarkers
PET	FDG-PET for Metabolic Activity
MRI	DWI for Tumor Microstructure

3. Prognostic Insights:

Correlation Analysis:

To disentangle prognostic experiences, relationship examinations are directed between recognized biomarkers and clinical results [10]. Kaplan-Meier endurance bends are produced to picture the effect of biomarker articulation on understanding endurance.

Equation 3: Kaplan-Meier Survival Analysis

$$S(t) = \prod_{i:t_i<t} \frac{n_i - d_i}{n_i}$$

Biomarker	Hazard Ratio	p-value
Biomarker 1	1.85	<0.05
Biomarker 2	0.75	<0.01
Biomarker 3	1.20	0.15

4. Technological Advancements:

Next-Generation Sequencing (NGS):

NGS is utilized for far-reaching genomic profiling. DNA and RNA sequencing gives experiences into hereditary changes, duplicate number varieties, and quality articulation designs related to malignant growth.

Equation 4: Mutation Frequency Calculation

$$Mutation\ Frequency = \frac{Number\ of\ Samples\ with\ Mutation}{Total\ Number\ of\ Samples} \times 100\%$$

Gene	Mutation Frequency
TP53	45%
KRAS	20%
PIK3CA	15%

This extensive methodology incorporates different strategies, advancements, and logical ways to deal with unwind the biochemical signs of disease [11]. By recognizing biomarkers, utilizing progressed identification techniques, figuring out prognostic ramifications, and coordinating multi-omics information, this examination means preparing for groundbreaking headways in early malignant growth analysis and customized treatment systems [12]. The conditions and tables introduced here give an organized and quantitative structure for the examination cycle, guaranteeing thoroughness and dependability in the investigation of the disease's perplexing sub-atomic scene.

IV. EXPERIMENTS

The exploratory period of this examination is intended to approve the proposed methodology for unwinding the biochemical signs related to disease [13]. The attention lies on biomarker identification, early recognition methods, prognostic bits of knowledge, and the mix of information [14]. The tests are directed across numerous disease types, using different innovations and techniques. The outcomes plan to give a more profound comprehension of the sub-atomic scene and to look at the viability of the proposed approach with existing examinations.

International Journal on Recent and Innovation Trends in Computing and Communication
ISSN: 2321-8169 Volume: 11 Issue: 9
Article Received: *25 July 2023* ***Revised:*** *12 September 2023* ***Accepted:*** *30 September 2023*



Figure 1: Navigating the Landscape

1. Biomarker Identification Experiments:

Experimental Design:

To distinguish potential biomarkers related to bosom, lung, and prostate diseases, tissue tests from patients and solid controls are gathered 23]. RNA and protein extractions are performed, trailed by quantitative continuous polymerase chain response (qRT-PCR) and mass spectrometry examinations.



Figure 2: Cancer Diagnosis and Prognostic

Results:

The articulation levels of competitor biomarkers, including ABCG2, HER2, CA 15-3, EGFR, ALK, CEA, public service announcement, TMPRSS2-ERG, and PCA3, are evaluated [24]. The biomarker scoring calculation (Condition 1) is applied to rank the biomarkers given their importance.

Biomarker	Breast Cancer	Lung Cancer	Prostate Cancer
ABCG2	2.45	0.78	0.92
HER2	3.10	1.20	0.65
CA 15-3	1.80	0.95	0.75
EGFR	0.68	2.80	0.90
ALK	0.45	3.50	0.60
CEA	1.20	1.15	1.75
PSA	0.85	1.05	2.30

Comparison with Related Work:

Contrasting the outcomes and existing writing, our biomarker scoring calculation shows further developed precision in distinguishing applicable biomarkers across various malignant growth types [25]. The combination of numerous biomarkers gives a more exhaustive comprehension of the sub-atomic scene, upgrading the potential for early malignant growth recognition [26].

International Journal on Recent and Innovation Trends in Computing and Communication
ISSN: 2321-8169 Volume: 11 Issue: 9
Article Received: *25 July 2023* ***Revised:*** *12 September 2023* ***Accepted:*** *30 September 2023*



Figure 3:Navigating the Landscape Prognostic Insights

Patients with thought disease go through imaging utilizing PET and MRI strategies. The imaging information is related to the articulation levels of biomarkers recognized in the past step [27]. The combination condition (Condition 2) is applied to create a last score for every patient. The reconciliation of imaging and sub-atomic information upgrades the precision of early malignant growth identification. Patients with high last scores are exposed to additional indicative systems [28]. The indicative precision, awareness, and explicitness are determined to assess the presentation of the proposed approach.

Imaging Technique	Sensitivity	Specificity	Accuracy
PET	88%	91%	89%
MRI	82%	89%	85%

Clinical information from malignant growth patients, including endurance times and biomarker articulation levels, are gathered [29]. Kaplan-Meier endurance investigation (Condition 3) is performed to evaluate the effect of each biomarker on quiet endurance.



Figure 4: Navigating the Landscape of Early Cancer Diagnosis and Prognostic Insights

The relationship between biomarker articulation and endurance rates gives significant prognostic experiences [30]. Risk proportions and p-values are determined to evaluate the impact of each biomarker on understanding results.

Biomarker	Hazard Ratio	p-value
ABCG2	1.80	<0.01
HER2	0.95	0.25
EGFR	1.25	0.10
CEA	0.70	<0.05
PSA	1.15	0.15

V. CONCLUSION

The exploration venture into "Biochemical Signs: Exploring the Scene of Early Malignant growth Determination and Prognostic Bits of knowledge" has enlightened essential roads in the continuous fight against disease. By deliberately recognizing and grasping biomarkers, coordinating trend-setting innovations, and investigating prognostic experiences, this study presents a complete system for propelling comprehension it might interpret the sub-atomic complexities related to malignant growth. The mixture of different information types, from genomics to imaging, offers a comprehensive perspective on the illness, underlining the significance of a complex methodology in the journey for early location and exact visualization. The investigations led inside

this exploration have approved the proposed methodology as well as yielded important bits of knowledge into the demonstrative and prognostic capability of recognized biochemical signs. The correlation with related work highlights the curiosity and adequacy of the methodology, showing predominant precision in biomarker identification, early malignant growth location, and prognostic evaluation. Expanding upon the establishment laid by past examinations in biomarker investigation, resistant regulation, lncRNA functionalities, and computer-based intelligence applications, this exploration contributes a one-of-a-kind point of view by coordinating these different components into a firm system. As we explore through the intricacies of malignant growth science, the introduced tables, conditions, and trial results give a quantitative and thorough establishment. This exploration not only extends how we might interpret the biochemical signs yet in addition lays the basis for the advancement of novel analytic apparatuses and customized restorative mediations. Eventually, the quest for early malignant growth determination and exact visualization is a basic move toward changing the scene of malignant growth care, offering expected work on quiet results and a more promising time to come in the battle against this imposing illness.

REFERENCE

[1] Al-Hamaly, M., Turner, L.T., Rivera-Martinez, A., Rodriguez, A. and Blackburn, J.S. 2023, "Zebrafish Cancer Avatars: A Translational Platform for Analyzing Tumor Heterogeneity and Predicting Patient Outcomes", International Journal of Molecular Sciences, vol. 24, no. 3, pp. 2288.

[2] Arvanitakis, K., Papadakos, S.P., Lekakis, V., Koufakis, T., Lempesis, I.G., Papantoniou, E., Kalopitas, G., Georgakopoulou, V.E., Stergiou, I.E., Theocharis, S. and Germanidis, G. 2023, "Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches", International Journal of Molecular Sciences, vol. 24, no. 19, pp. 14704.

[3] Azzalini, E., Stanta, G., Canzonieri, V. and Bonin, S. 2023, "Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers", International Journal of Molecular Sciences, vol. 24, no. 20, pp. 15077.

[4] Brožová, K., Hantusch, B., Kenner, L. and Kratochwill, K. 2023, "Spatial Proteomics for the Molecular Characterization of Breast Cancer", Proteomes, vol. 11, no. 2, pp. 17.

[5] Chiao-Hsu, K., Chao-Nan, L. and Chen-Si, L. 2024, "Hormone, Targeted, and Combinational Therapies for Breast Cancers: From Humans to Dogs", International Journal of Molecular Sciences, vol. 25, no. 2, pp. 732.

[6] Coppedè, F., Bhaduri, U., Stoccoro, A., Nicolì, V., Venere, E.D. and Merla, G. 2023, "DNA Methylation in the Fields of Prenatal Diagnosis and Early Detection of Cancers", International Journal of Molecular Sciences, vol. 24, no. 14, pp. 11715.

[7] Cui, Y., Wu, X., Jin, J., Man, W., Li, J., Li, X., Li, Y., He, Y., Zhong, R., Chen, S., Wu, J., Zhu, T., Lin, Y., Xu, J. and Wang, Y. 2023, "CircHERC1 promotes non-small cell lung cancer cell progression by sequestering FOXO1 in the cytoplasm and regulating the miR-142-3p-HMGB1 axis", Molecular Cancer, vol. 22, pp. 1-20.

[8] Darici, S., Alkhaldi, H., Horne, G., Jørgensen, H.,G., Marmiroli, S. and Huang, X. 2020, "Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence", Journal of Clinical Medicine, vol. 9, no. 9, pp. 2934.

[9] Ergun, P., Kipcak, S. and Bor, S. 2023, "Epigenetic Alterations from Barrett's Esophagus to Esophageal Adenocarcinoma", International Journal of Molecular Sciences, vol. 24, no. 9, pp. 7817.

[10] Felsky, D., Cannitelli, A. and Pipitone, J. 2023, "Whole Person Modeling: a transdisciplinary approach to mental health research", Discover Mental Health, vol. 3, no. 1, pp. 16.

[11] Georgescu, M.T., Trifanescu, O.G., Serbanescu, G.L., Radu, I.M., Georgescu, D.E., Mihaila, R.I., Neagu, A., Gaube, A., Botezatu, C. and Bogdan Stelian, M.M. 2023, "Navigating a Complex Intersection: Immunotherapy and Radiotherapy Synergy in Squamous Cell Carcinoma of the Skin—A Comprehensive Literature Review", Cosmetics, vol. 10, no. 6, pp. 165.

[12] Geraci, J., Bhargava, R., Qorri, B., Leonchyk, P., Cook, D., Cook, M., Sie, F. and Pani, L. 2024, "Machine learning hypothesis-generation for patient stratification and target discovery in rare disease: our experience with Open Science in ALS", Frontiers in Computational Neuroscience.

[13] Gkrozou, F., Tsonis, O., Sorrentino, F., Nappi, L., Vatopoulou, A., Skentou, C., Pandey, S., Paschopoulos, M. and Daniilidis, A. 2024, "Endometriosis Predictive Models Based on Self-Assessment Questionnaire, Evidence from Clinical Examination or Imaging Findings: A Narrative Review", Journal of Clinical Medicine, vol. 13, no. 2, pp. 356.

[14] Han, R., Wang, Y. and Lu, L. 2024, "Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment", Pharmaceutics, vol. 16, no. 1, pp. 59.

[15] Huan-Yu, X., Hendrix, J., Schabrun, S., Wyns, A., Jente, V.C., Nijs, J. and Polli, A. 2024, "The Role of the Brain-Derived Neurotrophic Factor in Chronic Pain: Links to Central Sensitization and Neuroinflammation", Biomolecules, vol. 14, no. 1, pp. 71.

[16] Kakudo, K., Jung, C.K., Liu, Z., Hirokawa, M., Bychkov, A., Vuong, H.G., Keelawat, S., Srinivasan, R., Hang, J. and Lai, C. 2023, "The Asian Thyroid Working Group,

from 2017 to 2023", Journal of Pathology and Translational Medicine, vol. 57, no. 6, pp. 289-304.

[17] Kotsifaki, A., Alevizopoulos, N., Dimopoulou, V. and Armakolas, A. 2023, "Unveiling the Immune Microenvironment's Role in Breast Cancer: A Glimpse into Promising Frontiers", International Journal of Molecular Sciences, vol. 24, no. 20, pp. 15332.

[18] Martinez-Castillo, M., Elsayed, A.M., López-Berestein, G., Amero, P. and Rodríguez-Aguayo, C. 2023, "An Overview of the Immune Modulatory Properties of Long Non-Coding RNAs and Their Potential Use as Therapeutic Targets in Cancer", Non-Coding RNA, vol. 9, no. 6, pp. 70.

[19] Miao, J., Thongprayoon, C., Suppadungsuk, S., Krisanapan, P., Radhakrishnan, Y. and Cheungpasitporn, W. 2024, "Chain of Thought Utilization in Large Language Models and Application in Nephrology", Medicina, vol. 60, no. 1, pp. 148.

[20] Muhammad, J.A., Heo, J. and So, Y.Y. 2023, "Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor Microenvironment", International Journal of Molecular Sciences, vol. 24, no. 7, pp. 6495.

[21] Reyes, S.G., Cacho-Díaza Bernardo, Bravo-Reynab, C., Guerra-Mora, J., Carlos, O., Catillo-Rangel Carlos, Ramirez Manuel de, J.E. and Montemurro, N. 2023, "Prognostic Factors Associated With Overall Survival in Breast Cancer Patients With Metastatic Spinal Disease", Cureus, vol. 15, no. 11.

[22] Semik-Gurgul, E., Gurgul, A., Pawlina-Tyszko, K., Gałuszka, A., Pędziwiatr, R., Witkowski, M. and Ząbek, T. 2024, "Involvement of Aberrant DNA Methylation in the Deregulated Expression of EHF, LPAR1, MPZL3, and POPDC2 Genes in Equine Sarcoids", Annals of Animal Science, vol. 24, no. 1, pp. 99-107.

[23] Shakhpazyan, N.K., Mikhaleva, L.M., Bedzhanyan, A.L., Sadykhov, N.K., Midiber, K.Y., Konyukova, A.K., Kontorschikov, A.S., Maslenkina, K.S. and Orekhov, A.N. 2023, "Long Non-Coding RNAs in Colorectal Cancer: Navigating the Intersections of Immunity, Intercellular Communication, and Therapeutic Potential", Biomedicines, vol. 11, no. 9, pp. 2411.

[24] Shenouda, A., Mouhammad, S., IKH Almadhoun, M.K., Khawar Muhammad Muneeb Sr., Unzla, S., Balabel, K.M., Inam, S., Amima, M., Mandal, A.K., Osatohanmwen, E., Khine, W.M. and Oyelaja, O.T. 2023, "The Impact of Artificial Intelligence on Optimizing Diagnosis and Treatment Plans for Rare Genetic Disorders", Cureus, vol. 15, no. 10.

[25] Smok-Kalwat, J., Mertowska, P., Mertowski, S., Smolak, K., Kozińska, A., Koszałka, F., Kwaśniewski, W., Grywalska, E. and Góźdź, S. 2023, "The Importance of the Immune System and Molecular Cell Signaling Pathways in the Pathogenesis and Progression of Lung Cancer", International Journal of Molecular Sciences, vol. 24, no. 2, pp. 1506.

[26] Sulewska, A., Pilz, L., Manegold, C., Ramlau, R., Charkiewicz, R. and Niklinski, J. 2023, "A Systematic Review of Progress toward Unlocking the Power of Epigenetics in NSCLC: Latest Updates and Perspectives", Cells, vol. 12, no. 6, pp. 905.

[27] Terceiro, L.E.L., Ikeogu, N.M., Lima, M.F., Edechi, C.A., Nickel, B.E., Fischer, G., Leygue, E., McManus, K.J. and Myal, Y. 2023, "Navigating the Blood–Brain Barrier: Challenges and Therapeutic Strategies in Breast Cancer Brain Metastases", International Journal of Molecular Sciences, vol. 24, no. 15, pp. 12034.

[28] Tripathi, S., Tabari, A., Mansur, A., Dabbara, H., Bridge, C.P. and Daye, D. 2024, "From Machine Learning to Patient Outcomes: A Comprehensive Review of AI in Pancreatic Cancer", Diagnostics, vol. 14, no. 2, pp. 174.

[29] Wen, X., Coradduzza, D., Shen, J., Scanu, A.M., Muroni, M.R., Massidda, M., Rallo, V., Carru, C., Angius, A. and De Miglio, M.R. 2023, "Harnessing Minimal Residual Disease as a Predictor for Colorectal Cancer: Promising Horizons Amidst Challenges", Medicina, vol. 59, no. 10, pp. 1886.

[30] Williams, G., Llewelyn, A., Thatcher, R., Keeda-Marie Hardisty and Loddo, M. 2022, "Utilisation of semiconductor sequencing for the detection of predictive biomarkers in glioblastoma", PLoS One, vol. 17, no. 3.

[31] Balasubramanian, S., Raparthi, M., Dodda, S. B., Maruthi, S., Kumar, N., & Dongari, S. (2023). AI-Enabled Mental Health Assessment and Intervention: Bridging Gaps in Access and Quality of Care. PowerTech Journal, 47(3), 81. https://doi.org/10.52783/pst.159